Phone: 203-676-3676
Website: http://www.newhavenpharma.com

Contact(s)
Harry H. Penner, CEO - [email protected]

General Information
New Haven Pharmaceuticals, Inc. (NHP) develops proprietary, controlled release specialty pharmaceuticals based on approved or GRAS (“Generally Recognized as Safe”) active pharmaceutical ingredients for use in new therapeutic indications. NHP’s novel product pipeline is built on three licenses from Yale University and Micropump® Aspirin, the world’s only 24-hour controlled-release aspirin, licensed from Flamel Technologies.

An NDA filing on the Company’s lead product, NHP-554C, a novel anti-platelet therapy, is expected in 2012 followed by a US launch in 2013, and an EU launch is being planned for 2012 based upon an approved Marketing Authorization Application (“MAA”) covering nine EU countries.

Research Activities
NHP-229 Technology
NHP is developing a controlled-release formulation of zinc salts for breakthrough GERD (Gastro Esophageal Reflux Disease) based on proprietary technology from Yale University. NHP-229 is being developed as adjunct therapy to proton pump inhibitors (e.g., Nexium) and as a stand-alone GERD therapy for adults and children. An NDA filing is planned in 2015. NHP-229 technology is also incorporated into other NHP products to enhance their GI safety.

Back